A Phase 1 Study Evaluating Safety Tolerability and Pharmacokinetics of Escalating Doses of AGS62P1 Given as Monotherapy in Subjects with Acute Myeloid Leukemia (AML)

Brief description of study

The main purpose of this study is to evaluate the safety and tolerability of the investigational drug, AGS62P1 (a monoclonal cytotoxic antibody agent that targets FLT3 which is a common mutation in up to 30% of AML patients) in patients with AML.  Having FLT3 mutation is not a requirement to participate in the study since FLT3 can be upregulated post chemotherapy regardless of its mutation status.


Clinical Study Identifier: s16-02097
ClinicalTrials.gov Identifier: NCT02864290
Principal Investigator: Mohammad Maher Abdul Hay
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.